QL04AASelektiva immunsuppressiva medel
QL04ABTumörnekrosfaktor alfa (TNF-alfa) hämmare
QL04ACInterleukinhämmare
QL04ADKalcineurinhämmare
QL04AESfingosin-1-fosfat (S1P) receptormodulatorer
QL04AFJanus-associerat kinas (JAK) hämmare
QL04AGMonoklonala antikroppar
QL04AHMammalian target of rapamycin (mTOR) kinashämmare
QL04AJKomplementhämmare
QL04AKDihydroorotatdehydrogenas (DHODH) hämmare
QL04ALNeonatal Fc-receptor (FcRn) hämmare
QL04AXÖvriga immunsuppressiva medel
QL04AG01Muromonab-CD3
QL04AG02Efalizumab
QL04AG03Natalizumab
QL04AG04Belimumab
QL04AG05Vedolizumab
QL04AG06Alemtuzumab
QL04AG07Begelomab
QL04AG08Okrelizumab
QL04AG09Emapalumab
QL04AG10Inebilizumab
QL04AG11Anifrolumab
QL04AG12Ofatumumab
QL04AG13Teprotumumab
QL04AG14Ublituximab
QL04AG15Divozilimab
QL04AG16Rozanolixizumab
QL04AG17Seniprutug
QL04AG18Sibeprenlimab
QL04AG19Axatilimab
QL04AG90Cirevetmab